Bellus Health Inc.
- Address
- 275 Armand-Frappier Blvd
Sponsor Overview
Specializations
Respiratory Medicine
Bellus Health Inc. focuses on refractory chronic cough, including unexplained chronic cough, with clinical research centered on persistent cough burden in adults.
- Chronic cough
- Refractory chronic cough
- Unexplained chronic cough
The sponsor’s research activity in this area reflects a concentrated interest in conditions where cough remains difficult to control and is associated with ongoing symptom impact.
Symptom Control and Cough Frequency Assessment
Its trials examine changes in 24-hour cough frequency as a key clinical outcome, highlighting interest in measurable symptom reduction for adults living with chronic cough disorders.
- Cough frequency
- Symptom burden
- Adult respiratory symptoms
This focus places emphasis on cough-related endpoints that capture the daily impact of the condition across extended treatment periods.
Safety and Long-Term Tolerability
The sponsor also investigates the safety and tolerability of therapies intended for chronic cough, with attention to extended use in adult participants.
- Therapy safety
- Long-term tolerability
- Extended treatment exposure
These research interests are relevant to chronic respiratory symptom management, where sustained treatment use requires careful monitoring of adverse effects and overall treatment acceptability.
Adult Respiratory Clinical Development
Bellus Health Inc. supports clinical research in adult patients with persistent cough syndromes, contributing to therapeutic development in a narrowly defined respiratory population.
- Adult participants
- Persistent cough syndromes
- Respiratory symptom management
The funded studies reflect a medical focus on conditions that lack clear underlying causes or remain difficult to treat in standard care.
Sponsored Trials
| Trial Name | Country | Status |
|---|---|---|
| Phase 3 Randomized Double-Blind Study of Camlipixant (BLU-5937) Versus Placebo in Adults with Refractory or Unexplained Chronic Cough |  Czechia Germany Poland Slovakia | Not Recruiting |
| Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of Camlipixant in Adults with Refractory or Unexplained Chronic Cough |  Belgium France Hungary Poland Spain The Netherlands | Not Recruiting |
Data & Insights
This sponsor works with 1 molecule, of which 1 is not being studied by other sponsors.
This sponsor has worked with 91 sites across their trial portfolio.
Therapeutic Focus
- 1.Respiratory Tract Diseases2 trials277 other sponsors
Partnered Research Centres
91 centres- Address
- Calle Del Marques De La Valdavia 103 Bajo Local, 28100 Alcobendas
- Address
- Ul. Polskiego Czerwonego Krzyza 26, 33-100 Tarnow
- Address
- Hradska Cesta 2, 060 01 Kežmarok
- Address
- Deltalaan 1, 8800 Roeselare
- Address
- President Kennedylaan 4, 8500 Kortrijk
Want to get in touch with this sponsor?
Send a question and we'll pass it on to Bellus Health Inc..
Need a custom report on this sponsor?
Competitive positioning, market entry, partnership opportunities — tell us the question.
Is something out of date?
Tell us what needs correcting and we'll update this profile.